Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: The European Anderson-Fabry Disease Survey

Heart

Volumn 97, Issue 23, 2011, Pages 1957-1960

  Elliott, Perry ^a   Baker, Robert ^b   Pasquale, Ferdinando ^a   Quarta, Giovanni ^a   Ebrahim, Hatim ^b   Mehta, Atul B ^b   Hughes, Derralynn A ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE;

A GAL A GENE; ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DNA POLYMORPHISM; FABRY DISEASE; FEMALE; GENE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC SCREENING; GENETIC VARIABILITY; HEALTH SURVEY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL;

AGED; ALPHA-GALACTOSIDASE; CARDIOMYOPATHY, HYPERTROPHIC; CROSS-SECTIONAL STUDIES; EUROPE; FABRY DISEASE; FEMALE; GENETIC TESTING; HUMANS; MALE; MIDDLE AGED; MUTATION; PREVALENCE;

EID: 80655147029     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2011-300364     Document Type: Article

References (24)

1. Zarate YA, Hopkin RJ. Fabry's disease. Lancet 2008;372:1427-35.
2. Linhart A, Elliott PM. The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart 2007;93:528-35. (Pubitemid 46631530)
3. Mehta A, Clarke JT, Giugliani R, et al. FOS Investigators. Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey. J Med Genet 2009;46:548-52.
4. Imbriaco M, Pisani A, Spinelli L, et al. Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study. Heart 2009;95:1103-7.
5. Hughes DA, Elliott PM, Shah J, et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebocontrolled clinical trial of agalsidase alfa. Heart 2008;94:153-8. (Pubitemid 351211719)
6. Nakao S, Takenaka T, Maeda M, et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 1995;333:288-93.
7. Sachdev B, Takenaka T, Teraguchi H, et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 2002;105:1407-11. (Pubitemid 34263268)
8. Chimenti C, Pieroni M, Morgante E, et al. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation 2004;110:1047-53. (Pubitemid 39319001)
9. Arad M, Maron BJ, Gorham JM, et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 2005;352:362-72.
10. Morita H, Larson MG, Barr SC, et al. Single-gene mutations and increased left ventricular wall thickness in the community: the Framingham Heart Study. Circulation 2006;113:2697-705. (Pubitemid 43947987)
11. Monserrat L, Gimeno-Blanes JR, Mar? ́n F, et al. Prevalence of Fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2007;50:2399-403. (Pubitemid 50011583)
12. Ommen SR, Nishimura RA, Edwards WD. Fabry disease: a mimic for obstructive hypertrophic cardiomyopathy? Heart 2003;89:929-30. (Pubitemid 36920824)
13. Rolfs A, Bottcher T, Zschiesche M, et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 2005;366:1794-6. (Pubitemid 41642643)
14. Morgan SH, Rudge P, Smith SJ, et al. The neurological complications of Anderson-Fabry disease (α-galactosidase A deficiency) - investigation of symptomatic and presymptomatic patients. Q J Med 1990;75:491-504.
15. Eng CM, Niehaus DJ, Enriquez AL, et al. Fabry disease: twenty-three mutations including sense and antisense CpG alterations and identification of a deletional hot-spot in the alpha-galactosidase A gene. Hum Mol Genet 1994;3:1795-9. (Pubitemid 24310473)
16. Davies JP, Winchester BG, Malcolm S. Mutation analysis in patients with the typical form of Anderson-Fabry disease. Hum Mol Genet 1993;2:1051-3. (Pubitemid 23216645)
17. Eng CM, Ashley GA, Burgert TS, et al. Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes. Mol Med 1997;3:174-82. (Pubitemid 27215284)
18. Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004;34:236-42.
19. Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 2006;79:31-40. (Pubitemid 43927374)
20. Hwu WL, Chien YH, Lee NC, et al. Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4 +919G>A). Hum Mutat 2009;30:1397-405.
21. Linthorst GE, Bouwman MG, Wijburg FA, et al. Screening for Fabry disease in highrisk populations: a systematic review. J Med Genet 2010;47:217-22.
22. Hagège AA, Caudron E, Damy T, et al. FOCUS study investigators. Screening patients with hypertrophic cardiomyopathy for Fabry disease using a filter-paper test: the FOCUS study. Heart 2011;97:131-6.
23. Mehta A, Beck M, Elliott P, et al. Fabry Outcome Survey investigators. Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet 2009;374:1986-96.
24. Linhart A, Kampmann C, Zamorano JL, et al. European FOS Investigators. Cardiac manifestations of AndersoneFabry disease: results from the international Fabry outcome survey. Eur Heart J 2007;28:1228-35. (Pubitemid 47343855)